Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
134,608,103
-
Total 13F shares
-
65,465,348
-
Share change
-
+65,465,348
-
Total reported value
-
$844,863,000
-
Price per share
-
$12.93
-
Number of holders
-
45
-
Value change
-
+$844,863,243
-
Number of buys
-
45
Institutional Holders of Tango Therapeutics, Inc. - Common Stock (TNGX) as of Q3 2021
As of 30 Sep 2021,
Tango Therapeutics, Inc. - Common Stock (TNGX) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,465,348 shares.
The largest 10 holders included
TRV GP IV, LLC, BOXER CAPITAL, LLC, FMR LLC, Casdin Capital, LLC, HHLR ADVISORS, LTD., Cormorant Asset Management, LP, Southpoint Capital Advisors LP, RA CAPITAL MANAGEMENT, L.P., Bain Capital Life Sciences Investors, LLC, and Avoro Capital Advisors LLC.
This page lists
45
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.